- Home
- JEQ vs MAIA Comparison
JEQ vs MAIA Comparison
Compare JEQ & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JEQ
- MAIA
- Stock Information
- Founded
- JEQ 1990
- MAIA 2018
- Country
- JEQ United States
- MAIA United States
- Employees
- JEQ N/A
- MAIA N/A
- Industry
- JEQ Air Freight/Delivery Services
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- JEQ Consumer Discretionary
- MAIA Health Care
- Exchange
- JEQ Nasdaq
- MAIA Nasdaq
- Market Cap
- JEQ 99.8M
- MAIA 46.7M
- IPO Year
- JEQ N/A
- MAIA 2022
- Fundamental
- Price
- JEQ $7.51
- MAIA $1.94
- Analyst Decision
- JEQ
- MAIA
- Analyst Count
- JEQ 0
- MAIA 0
- Target Price
- JEQ N/A
- MAIA N/A
- AVG Volume (30 Days)
- JEQ 32.0K
- MAIA 526.7K
- Earning Date
- JEQ 01-01-0001
- MAIA 08-08-2025
- Dividend Yield
- JEQ 7.05%
- MAIA N/A
- EPS Growth
- JEQ N/A
- MAIA N/A
- EPS
- JEQ N/A
- MAIA N/A
- Revenue
- JEQ N/A
- MAIA N/A
- Revenue This Year
- JEQ N/A
- MAIA N/A
- Revenue Next Year
- JEQ N/A
- MAIA N/A
- P/E Ratio
- JEQ N/A
- MAIA N/A
- Revenue Growth
- JEQ N/A
- MAIA N/A
- 52 Week Low
- JEQ $4.99
- MAIA $1.40
- 52 Week High
- JEQ $6.39
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- JEQ 68.54
- MAIA 61.28
- Support Level
- JEQ $6.94
- MAIA $1.60
- Resistance Level
- JEQ $7.62
- MAIA $1.95
- Average True Range (ATR)
- JEQ 0.14
- MAIA 0.11
- MACD
- JEQ 0.02
- MAIA 0.02
- Stochastic Oscillator
- JEQ 64.52
- MAIA 94.39
About JEQ abrdn Japan Equity Fund Inc.
Aberdeen Japan Equity Fund Inc is a United States-based closed-end diversified management investment company. Its investment objective is to outperform over the long term, on a total return basis (including appreciation and dividends), the Tokyo Stock Price Index ("TOPIX"). The fund seeks to achieve its investment objective by investing a majority of its assets, in equity securities of companies listed on the Tokyo Stock Exchange or listed on the over-the-counter market in Japan or listed on other stock exchanges in Japan. The portfolio of investments is spread across Consumer Discretionary, Industrials, Information Technology, Financials, and other sectors.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.